JP5727379B2 - 変形性関節症の治療 - Google Patents

変形性関節症の治療 Download PDF

Info

Publication number
JP5727379B2
JP5727379B2 JP2011541030A JP2011541030A JP5727379B2 JP 5727379 B2 JP5727379 B2 JP 5727379B2 JP 2011541030 A JP2011541030 A JP 2011541030A JP 2011541030 A JP2011541030 A JP 2011541030A JP 5727379 B2 JP5727379 B2 JP 5727379B2
Authority
JP
Japan
Prior art keywords
csf
antibody
seq
amino acid
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011541030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512815A (ja
JP2012512815A5 (enExample
Inventor
アラン ハミルトン，ジョン
アラン ハミルトン，ジョン
デイビッド クック，アンドリュー
デイビッド クック，アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5727379(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of JP2012512815A publication Critical patent/JP2012512815A/ja
Publication of JP2012512815A5 publication Critical patent/JP2012512815A5/ja
Application granted granted Critical
Publication of JP5727379B2 publication Critical patent/JP5727379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011541030A 2008-12-22 2009-12-21 変形性関節症の治療 Active JP5727379B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US61/139,679 2008-12-22
US16448609P 2009-03-30 2009-03-30
US61/164,486 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015031198A Division JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療

Publications (3)

Publication Number Publication Date
JP2012512815A JP2012512815A (ja) 2012-06-07
JP2012512815A5 JP2012512815A5 (enExample) 2013-02-14
JP5727379B2 true JP5727379B2 (ja) 2015-06-03

Family

ID=42286786

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011541030A Active JP5727379B2 (ja) 2008-12-22 2009-12-21 変形性関節症の治療
JP2015031198A Pending JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療
JP2017114806A Active JP6458086B2 (ja) 2008-12-22 2017-06-12 変形性関節症の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015031198A Pending JP2015143233A (ja) 2008-12-22 2015-02-20 変形性関節症の治療
JP2017114806A Active JP6458086B2 (ja) 2008-12-22 2017-06-12 変形性関節症の治療

Country Status (19)

Country Link
US (4) US9243061B2 (enExample)
EP (2) EP2376121B2 (enExample)
JP (3) JP5727379B2 (enExample)
KR (2) KR101799264B1 (enExample)
CN (2) CN106397591A (enExample)
AU (1) AU2009329814B2 (enExample)
BR (1) BRPI0918356B1 (enExample)
CA (1) CA2746827C (enExample)
CY (1) CY1117698T1 (enExample)
DK (1) DK2376121T4 (enExample)
ES (2) ES2572368T5 (enExample)
HK (1) HK1226938A1 (enExample)
HR (1) HRP20160577T4 (enExample)
HU (1) HUE028615T2 (enExample)
PL (1) PL2376121T5 (enExample)
RU (2) RU2712273C2 (enExample)
SI (2) SI2376121T1 (enExample)
SM (1) SMT201600156B (enExample)
WO (1) WO2010071924A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ234479A (en) 1989-07-14 1992-03-26 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
DK0486572T3 (da) 1989-08-11 1998-05-04 Amrad Corp Ltd Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
CA2555688C (en) † 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
WO2006023412A2 (en) 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR101481844B1 (ko) * 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP2010527939A (ja) * 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
MX2010010503A (es) † 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
EP3381471B1 (en) † 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
KR101898982B1 (ko) 2018-09-14
WO2010071924A1 (en) 2010-07-01
CN102271705A (zh) 2011-12-07
HK1226938A1 (en) 2017-10-13
DK2376121T3 (en) 2016-05-30
EP3056217A1 (en) 2016-08-17
ES2572368T5 (es) 2021-12-16
EP2376121B1 (en) 2016-03-09
EP2376121A1 (en) 2011-10-19
JP2015143233A (ja) 2015-08-06
JP6458086B2 (ja) 2019-01-23
JP2017200933A (ja) 2017-11-09
JP2012512815A (ja) 2012-06-07
US20200247895A1 (en) 2020-08-06
RU2712273C2 (ru) 2020-01-28
BRPI0918356A2 (pt) 2020-10-06
CY1117698T1 (el) 2017-05-17
RU2016102339A (ru) 2018-11-21
SMT201600156B (it) 2016-08-31
BRPI0918356B1 (pt) 2022-03-08
KR20110128273A (ko) 2011-11-29
AU2009329814B2 (en) 2015-06-18
PL2376121T5 (pl) 2021-09-27
KR101799264B1 (ko) 2017-11-20
SI2376121T1 (sl) 2016-07-29
ES2572368T3 (es) 2016-05-31
US9243061B2 (en) 2016-01-26
CA2746827A1 (en) 2010-07-01
US20120003234A1 (en) 2012-01-05
US20180066062A1 (en) 2018-03-08
EP2376121B2 (en) 2021-06-09
PL2376121T3 (pl) 2016-12-30
EP2376121A4 (en) 2013-04-03
US20160185868A1 (en) 2016-06-30
CA2746827C (en) 2018-01-23
KR20170128630A (ko) 2017-11-22
AU2009329814A1 (en) 2010-07-01
HRP20160577T1 (hr) 2016-07-29
RU2011127334A (ru) 2013-01-27
HRP20160577T4 (hr) 2021-08-20
SI2376121T2 (sl) 2021-11-30
ES2886063T3 (es) 2021-12-16
CN106397591A (zh) 2017-02-15
HUE028615T2 (en) 2016-12-28
EP3056217B1 (en) 2021-06-30
RU2016102339A3 (enExample) 2019-07-29
DK2376121T4 (da) 2021-08-16

Similar Documents

Publication Publication Date Title
JP6458086B2 (ja) 変形性関節症の治療
EP2387418B1 (en) Pain treatment
EP2101780B1 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
AU2015224416B2 (en) Osteoarthritis treatment
HK1162336A (zh) 骨关节炎治疗
HK1162335A (en) Pain treatment
HK1162335B (en) Pain treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130731

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130829

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140919

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150402

R150 Certificate of patent or registration of utility model

Ref document number: 5727379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250